Clinical Trials Logo

Corneal Defect clinical trials

View clinical trials related to Corneal Defect.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05626478 Recruiting - Corneal Edema Clinical Trials

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT ID: NCT05204329 Recruiting - Cornea Clinical Trials

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

MSCSecretome
Start date: January 24, 2024
Phase: Early Phase 1
Study type: Interventional

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.

NCT ID: NCT04626583 Recruiting - Safety Clinical Trials

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

NCT ID: NCT04228926 Recruiting - Corneal Defect Clinical Trials

Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects

Start date: December 24, 2020
Phase: Phase 2
Study type: Interventional

The subjects of this study were patients who underwent corneal endothelial transplantation,who were randomly divided into 3 groups, 2 groups (0.002% and 0.004% ZKY001 eye drops) and 1 placebo control group.